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Simian virus 40 (SV40) large T antigen (LT) coding sequences were revealed in different 
human samples, whereas SV40 antibodies (Ab) were detected in human sera of cancer 
patients and healthy individuals, although with a lower prevalence. Previous studies car-
ried out by the neutralization assay gave a SV40 seroprevalence, in the general popula-
tion, up to 8%, although higher rates, 12%, were detected in kidney transplant children, 
in a group of HIV-positive patients, and in healthy females. In this study, serum samples 
from pregnant women, together with those from non-pregnant women, were analyzed to 
check the prevalence of IgG Ab reacting to SV40 LT antigens. Serum samples were col-
lected from pregnant and non-pregnant women, with the same mean age. Women were 
in the range of 15–48 years old. Samples were assayed by an indirect ELISA employing 
specific SV40 LT mimotopes as antigens, whereas functional analysis was performed 
by neutralization of the viral infectivity in cell cultures. As a control, sera were analyzed 
for Ab against BK polyomavirus (BKPyV), which is a human polyomavirus homologous 
to SV40. Statistical analyses employed chi-square with Yates’ correction, and Student’s 
t tests. Indirect ELISAs indicated that pregnant women tested SV40 LT-positive with a 
prevalence of 17% (23/134), whereas non-pregnant women had a prevalence of 20% 
(36/180) (P >  0.05). Ab against BKPyV were detected with a prevalence of 80% in 
pregnant women and with a prevalence of 78% in non-pregnant women. These data 
indicate that SV40 infects at a low prevalence pregnant women. We may speculate that 
SV40, or a close human polyomavirus still undetected, could be transmitted from mother 
to fetus.
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inTrODUcTiOn
Simian virus 40 (SV40) was detected in early poliovirus vaccines. SV40 was present as a natural 
infectious agent in kidney cells, from wild macaques, employed for the production of anti-polio 
vaccines. Millions of individuals between 1955 and 1963 were vaccinated with anti-polio vaccines 
with SV40 as contaminant. These vaccines, as well as other SV40-contaminated vaccines against 
hepatitis A virus, respiratory syncytial virus, and adenovirus, were sources of SV40 exposure for 
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the human population worldwide (1, 2). SV40 transforms in vitro 
cells of different types, including human cells, whereas in  vivo 
it induces multiple tumors in experimental animals (1, 3, 4). 
SV40 DNA sequences were detected in different normal speci-
mens from healthy subjects (5–10). Moreover, SV40 sequences 
were revealed by molecular biology techniques, in human 
cancers of distinct histotypes, such as brain and bone tumors, 
mesothelioma, different lymphoproliferative disorders, including 
non-Hodgkin lymphoma. Among SV40-positive tumors, brain 
tumors as ependymomas and choroid plexus papillomas, as well 
as osteosarcomas mainly affect children and adolescents (2). The 
association between pediatric tumors and SV40 suggests that the 
viral infection could be acquired during the pregnancy period 
or soon after the delivery of the offspring. It should be recalled 
that these human tumors correspond to the neoplasms that are 
induced by SV40 in experimentally inoculated rodents (11) or in 
transgenic mice with SV40 Tag under tissue-specific promoter–
enhancer (12, 13).
The World Health Organization/International Agency for 
Research on Cancer indicated that there is not enough firm 
evidence to classify SV40 as a carcinogenic viral agent of humans 
(14). Although SV40 infections have been documented in certain 
populations in different geographic regions, more studies are 
needed to investigate the prevalence of SV40 in humans and the 
natural history of this infection.
Seroprevalence surveys are a common approach to examine 
the distribution of a viral infection within a host population. 
The neutralization assay, which is considered in the field the 
most efficient and specific technique to detect SV40 antibodies 
(Ab) in human sera, was employed in several investigations. This 
method in US investigations gave a seroprevalence of SV40 Ab 
up to 8%, whereas in kidney transplant pediatric patients, HIV 
patients, and women with a Hispanic genetic background, a 
higher prevalence was detected (15). In Italy, SV40 prevalence 
was found, with the same technical approach, to be higher in the 
range of 12% (16). However, this technical approach has several 
disadvantages: it is expensive, lengthy, and because of the many 
different methodological tasks, it requires specialized trained 
personal. The neutralization assay disadvantages do not allow its 
use in serological surveys with a large sample size. SV40 Ab were 
detected using enzyme immunoassays (EIA) with SV40 antigens 
represented by virus-like particles (VLPs) or soluble VP1 capsid 
protein, as recombinant products. In EIA reactions, all VP Ab are 
detected, including non-neutralizing ones and those that recog-
nize cross-reacting antigens with other highly homologous poly-
omaviruses, such as BK virus (BKPyV) and JC virus (JCPyV). The 
cross-reactivity is the major limitation of this approach because it 
gives non-specific reactivity for SV40 (17–22).
Novel indirect ELISAs with specific SV40 mimotopes, as 
synthetic peptides, representing viral capsid proteins VP 1–3 
(23) and viral LT oncoprotein (24, 25) seems to circumvent these 
problems, i.e., the cross-reactivity among closely related poly-
omaviruses. Recent studies with these novel ELISAs documented 
SV40 Ab in healthy subjects with an estimated seroprevalence of 
18–20%.
Molecular biology and immunological investigations reported 
on the presence of SV40 footprints in samples from healthy 
subjects and patients who had not administered with SV40-
contaminated vaccines (24, 26). These studies indicate that the 
human-to-human contagion could be responsible of the SV40 
infection in the human population. At present, the prevalence 
of SV40 spread is much lower, about 18%, than that detected for 
other ubiquitous polyomaviruses, such as BKPyV, JCPyV, and 
Merkel cell polyomavirus (MCPyV), which is in the range of 80% 
(14, 23, 25).
In previous investigations, IgG serum Ab reacting with SV40 
VP mimotopes and with neutralization activity were reported in 
pregnant women and non-pregnant women. Herein, we report 
new data from the investigation, which determines the preva-
lence of Ab against SV40 LT, the viral oncoprotein, in pregnant 
women using a novel indirect ELISA with two synthetic peptides 
corresponding to SV40 LT mimotopes.
MaTerials anD MeThODs
study Design and setting
Samples were from our serum collections (23, 25, 27, 28). They 
were collected from pregnant women (n = 134) and non-pregnant 
women (n = 180) with a similar age. The mean age was 32 years 
(15–48 years). All serum samples (n = 314) were assayed by an 
indirect ELISA with mimotopes, represented by specific synthetic 
peptides, from SV40 large T antigen (LT).
Study participants provided written informed consent at the 
time of the hospital admission. Samples were collected from 
discarded sera, after routine clinical laboratory analyses, before 
their incineration. The Ethic Committee of Ferrara, approved the 
study, number 151078, on April 14, 2016.
indirect elisa
The indirect ELISA employed herein has been recently published 
(24, 25).
Peptide Design
Computer-assisted analyses enabled us to select two specific SV40 
LT peptides, known as A and D, respectively, which are encoded 
by the viral LT early gene. SV40 Tag mimotopes were compared 
with LT amino acids (a.a.) from human BKPyV and JCPyV 
polyomaviruses, which are highly homologous to SV40, as well 
as with other, less homologous, polyomaviruses.1 The a.a. residues 
of the two specific SV40 LT peptides showed low homology with 
BKPyV and JCPyV Tag. Preliminary ELISA results indicated that 
the two selected peptides did not cross-react with BKPyV and 
JCPyV hyperimmune sera employed as controls. The two A and 
D peptides map on the LT oncoprotein,2 as shown earlier (24, 25). 
The a.a. sequences of the two LT A and D peptides are as follows:
LT A: NH2-G S F Q A P Q S S Q S V H D H N Q P Y H I-COOH 
(Tag a.a. 669–689).
LT D: NH2-H E T G I D S Q S Q G S F Q A P Q S S Q S V H 
D-COOH (Tag a.a. 659–682).
1 http://blast.ncbi.nlm.nih.gov.
2 http://www.ncbi.nlm.nih.gov/nuccore.
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Mimotopes A and D overlap from Tag a.a.669 to 682. SV40 
LT synthetic peptides A and D were employed in indirect 
ELISAs (see below) because reacting specifically with a hyper-
immune serum of a rabbit immunized with the purified SV40 
LT protein (positive control sera) and with SV40 VP-positive 
human sera, tested earlier (23). SV40 LT A and D synthetic 
peptides did not react with BKPyV and JCPyV hyperimmune 
sera, employed as negative control. A human negative peptide, 
used as control, was the neuropeptide S (hNPS), a.a. sequence 
SFRNGVGTGMKKTSFQRAKS. This human neuropeptide is 
non-liked to SV40 (25). The synthetic peptides were from the 
University of Ferrara firm, the UFPeptides s.r.l., Ferrara, Italy.
Peptide Coating
Briefly, plates coated with synthetic peptides were used to reveal 
specific SV40 LT Ab in human serum samples. These SV40 LT 
A and D mimotopes are from the a.a. residues 669–689 (21 a.a.) 
and 659–682 (24 a.a.), respectively. ELISA plates (Nunc-immuno 
plate PolySorp, CelBio, Milan) were coated with 5  µg of the 
mimotope A or D, diluted in 100 µl of Coating Buffer 1×, pH 9.6 
(Candor Bioscience, Wangen, Germany). Plates were placed at 
4°C for 16 h.
Blocking Phase
To remove unattached peptide, plates were rinsed three times 
with Washing Buffer (Candor Bioscience, Wangen, Germany). 
Blocking was performed with 200 μl/well of blocking solution 
containing casein (Candor Bioscience, Wangen, Germany) at 
37°C for 90 min.
Primary Antibody
Then, plates were rinsed three times with Washing Buffer 
(Candor Bioscience, Wangen, Germany) using washing appa-
ratus (Thermo Electron Corp., model Well wash 4MK2, Vantaa, 
Finland). Different wells were covered with 100  µl containing 
the following sera: a positive control represented by the immune 
rabbit serum containing anti-SV40 LT Ab; the negative controls 
were immune sera with anti-BKPyV and anti-JCPyV Ab and 
three human serum samples tested SV40-negative in earlier stud-
ies (24, 25). Human serum samples from pregnant women and 
non-pregnant women were diluted in Low Cross-Buffer pH 7.2 
(Candor Bioscience, Wangen, Germany) at 1:20 and were added 
to the plate. Additional controls in each plate included a well with 
the secondary antibody only and other wells void of both primary 
and secondary Ab. The plate was incubated at 37°C for 90 min.
Secondary Antibody Addition
After 90 min of incubation, a triple rinsing cycle was repeated 
and then the secondary antibody solution was added to each 
well. The solution contained goat anti-human or goat anti-rabbit 
IgG heavy (H) and light (L) chain-specific peroxidase conjugate 
(Calbiochem-Merck, Darmstadt, Germany) diluted 1:10,000 in 
Low Cross-Buffer (Candor Bioscience, Wangen, Germany). The 
reaction mixture was incubated at room temperature for 90 min.
Optical Density (OD) Reading
At the end of the incubation period, the plates were rinsed 
three times with washing buffer and then treated with 100  µl 
of 2,2′-azino-bis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) 
solution (Sigma-Aldrich, Milan, Italy), which reacted with the 
peroxidase enzyme to yield the color reaction. The plate was then 
read spectrophotometrically (Thermo Electron Corp., model 
Multiskan EX, Vantaa, Finland) at a wavelength (λ) of 405 nm. 
This OD reading reflected the extent of immune complexes 
formed by the presence of specific Ab, which bound to the SV40 
LT synthetic peptide/epitopes/mimotopes.
Cutoff Determination
Cutoff values were determined for each assay using the OD reading 
of the three negative control sera, which were added to the SD and 
multiplied three times (+3 SD). The three SV40-negative control 
sera were selected from those below the cutoff value determined 
with second-degree polynomial regression by plotting the ranked 
net OD individual values for each peptide. The OD representation 
was obtained from a second-degree polynomial regression for LT 
A and D mimotopes, as reported before for BKPyV and MCPyV 
VLPs (24, 25). Our representations show an inflection point for 
peptide A and peptide D at 0.19–0.18, respectively. Immune 
serum samples were considered SV40 LT-positive when reacting 
to both peptides A and D, in three replica ELISA experiments 
carried out by three different operators.
hemagglutination (ha) assay and 
hemagglutination inhibition (hai) assay
In order to verify which sera from pregnant women were 
BKPyV-positive, HAI assays were carried out, as described before 
(23, 29). Briefly, BKPyV viral working stocks, employed for HAI, 
were obtained in infected Vero cells, purchased from the ATCC. 
BKPyV viral titer, determined by the HA assay was 1.6 ×  102 
hemagglutinating units, corresponding to 1.6  ×  106 plaque 
forming unit (PFU)/mL. BKPyV was employed as antigens in 
HA and HAI tests. HA and HAI titers for BKPyV were obtained 
as reported before (23, 29, 30). These assays allow the detection 
of serum Ab against the human polyomavirus BKPyV, which 
abolish its agglutination properties. The HA titer is the highest 
viral dilution that still hemagglutinates the human herytrocytes, 
whereas the HAI titer is the highest dilution of the immune serum 
under analysis that still inhibits completely the viral HA.
sV40 neutralization assay
CV-1 monkey kidney cells, which are cells permissive to SV40 
infection, were employed for the neutralization assay in vitro. The 
SV40 infectivity was scored as a reduction of the number of PFUs 
in CV-1 monolayers. The neutralization of the SV40 infectivity 
was assayed by mixing the human serum under analysis, diluted 
at 1:20 in phosphate buffered saline (PBS), with 5 × 104 PFUs of 
SV40; then, the solution was incubated at 37°C for 30 min. The 
solution was layered on the CV-1 monolayer for 2 h at 37°C. Then, 
the inoculum was discarded from the cells and the monolayer 
rinsed three times with DMEM. Each sample was analyzed 
twice. The controls were as follows: (i) CV-1 with PBS; (ii) SV40 
with PBS; (iii) SV40 with an immune human sample, the posi-
tive control; (iv) SV40 with a non-immune serum, the negative 
control. The appearance of the SV40 cytopathic effect (CPE) had 
inspected in CV-1 infected monolayers by a light microscope for 
TaBle 1 | Prevalence of immunoglobulin g antibodies reacting simian 
virus 40 (sV40) lT mimotopes in serum samples from pregnant and non-
pregnant women.
subject number of 
samples
Mean age 
(range) 
(years)
number of positive 
samples (%)
lT a lT D lT a + D
Pregnant women 134 32 (15–48) 32 (24) 31 (23) 23 (17)
Non-pregnant 
women
180 30 (18–40) 48 (27) 51 (28) 36 (20)
Human sera were from pregnant and non-pregnant women. No statistically significant 
differences of SV40 seroprevalence were detected between the two cohorts 
(P > 0.05). Statistical analysis was performed using the chi-square test with Yates’ 
correction.
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21  days. The neutralization assay was performed in triplicate, 
while the neutralizing activity of the serum under analysis was 
checked by the inhibition of SV40 CPE.
statistical analysis
The prevalence of SV40-positive serum samples from pregnant 
and non-pregnant women was determined using chi-square with 
Yates’ correction. The serologic profile of serum antibody reactiv-
ity to SV40 LT mimotopes was statistically analyzed using the 
Student’s t tests. All computational analyses were performed with 
Prism 6.0 (GraphPad software, San Diego, CA, USA). For all tests, 
P was considered to be statistically significant when P < 0.05.
resUlTs
igg ab reacting to sV40 lT Mimotopes in 
serum samples from Pregnant Women
Sera from pregnant women (n = 134) and non-pregnanat women 
(n = 180) were tested by indirect ELISAs for IgG Ab reactive to 
SV40 LT A and D synthetic peptides (Table 1). Pregnant women 
sera, diluted to 1/20, were assayed for their ability to react to 
SV40 LT A mimotope. Pregnant women samples tested positive 
for LT peptide A were 32 out of 134, with a prevalence of 24% 
(Table  1). ODs for SV40 LT-positive sera were in the range 
0.19–0.73 (Figure 1). Then, sera were assayed for the other SV40 
LT-specific peptide, the D mimotope. Samples reacted with the 
LT D peptide the similar prevalence, 23% (31/134) (Table 1) as 
it was detected for the LT A peptide. ODs range was 0.18–1.28 
(Figure 1). Serologic profiles are shown in Figure 1.
The human peptide hNPS, the negative control, did not react 
with human sera under analysis. OD values were in the range of 
0.050–0.095, an OD reading which is expected for human sera 
tested SV40-negative. The hyperimmune rabbit serum with Ab 
against SV40 LT had OD readings of 2.9 and 2.2 for peptides A and 
D, respectively. In our indirect ELISAs, the OD value of 0.18 is the 
cutoff for the SV40 LT-negative samples, with an OD < 0.18, and 
SV40 LT-positive samples, with an OD value >0.18. Control sera 
were six SV40 LT-positive human sera, which reacted with SV40 
VP mimotopes in previous investigations, together with a hyper-
immune serum of a rabbit immunized with purified SV40 LT pro-
tein. Herein, human sera tested SV40 LT-positive had OD values 
FigUre 1 | continued
up to 1.286, whereas human sera tested SV40 LT-negative had OD 
less than 0.18 (Figure 1). In our study, only those sera (n = 23) 
which tested positive for both SV40 LT mimotopes A and D, with 
an overall prevalence of 17%, were considered SV40 LT-positive 
(Table  1). The majority of serum samples (n =  102/134; 76%) 
that were found to be negative for the LT A peptide did not react 
to SV40 LT D antigen. The different prevalence of LT A-positive 
sera (32/134; 24%) and LT D-positive sera (31/134; 23%) was not 
significant (P > 0.05). The prevalence of 24 and 23% detected for 
the single peptide A and peptide D, respectively, did not differ 
TaBle 2 | Prevalence of antibodies (ab) against BKPyV using 
hemagglutination inhibition assay.
subject BKPyV ab positivea/analyzed sera (%)
Pregnant women 24/30 (80)
Non-pregnant women 39/50 (78)
The prevalence of Ab against BKPyV in sera samples of pregnant women was 
compared to that of non-pregnant women. Statistical analysis was performed with the 
chi-square test with Yates’ correction. No statistically significant differences of BKPyV 
seroprevalence, between the two cohorts (P > 0.05).
aBKPyV Ab-positive sera were at 1:20 dilution.
FigUre 1 | continued  
serologic profile of serum antibody reactivity to simian virus 40 (sV40) lT mimotopes. Immunologic data are from total samples of pregnant and 
non-pregnant women. Results are presented as optical density (OD) values at λ 405 nm for serum samples diluted 1:20 and assayed using indirect ELISAs. In the 
scatter dot plotting, each plot represents the dispersion of individual sample OD value to a mean level, indicated by the long horizontal line inside the scatter with 
SEM (31) marked by a short horizontal line for each age group. Data were analyzed with unpaired t test (OD mean, 95% CI). (a) OD values of antibodies  
(Ab) against SV40 mimotope LT A in pregnant women (0.19 OD, 95% CI = 0.11–0.28) was similar to that observed in non-pregnant women (0.22 OD, 95% 
CI = 0.19–0.24, P > 0.05). (B) The mean OD of sera against SV40 mimotope LT D in pregnant women (0.17, 95% CI = 0.14–0.19) was lower than that detected in 
non-pregnant women (0.20, 95% CI = 0.19–0.23, *P < 0.05). (c) OD values of Ab against SV40 mimotopes, both peptides LT A and LT D, found in pregnant 
women (0.18 OD, 95% CI = 0.14–0.23) were similar to those observed in non-pregnant women (0.21 OD, 95% CI = 0.20–0.23, P > 0.05).
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statistically from the prevalence of 17% (23/134) detected for 
samples found to be SV40-positive for both peptides A + D. In 
our indirect ELISA, SV40-positive sera had general spectropho-
tometric readings in the range of 0.18–1.28 OD.
Sera of non-pregnant women were analyzed by the same 
indirect ELISA with the SV40 LT mimotopes A and D. Samples 
of non-pregnant women had a prevalence of specific SV40 LT Ab 
of 20% (36/180) (Table 1).
hai Test for the Presence of neutralizing 
ab against BKV
The presence of BKPyV serum Ab in pregnant and non-pregnant 
women was determined using the HAI assay. Specifically, n = 30 
and n = 50 sera of pregnant women and non-pregnant women, 
diluted 1/20 in PBS, were incubated with BKPyV (8 HAU) virions 
for 1 h (30). Then, sera added to virions were assayed with human 
red cells, group 0, Rh+, for 5 h at +4°C. Among sera, 24 from 
pregnant women out of 30 (80%) and 39 from 50 of the non-
pregnant group (78%) inhibited the hemagglutination property of 
BKPyV (Table 2). The reproducibility of the serological results was 
assessed in three replica experiments carried out by independent 
operators with no data variability. Altogether, these assays allowed 
us to verify, which serum samples were SV40-positive only.
neutralization of sV40 infectivity  
in Permissive cells by serum ab  
from Pregnant Women
To verify the neutralization activity of SV40 immune sera from 
pregnant women, an inhibition test was performed (29). SV40 
immune sera (n = 4) from pregnant women and non-pregnant 
women (n =  4) with an OD (range OD =  0.193–0.876) were 
challenged to inhibit the SV40 CPE in CV1-infected monolayers. 
Together with SV40-positive sera, two additional SV40-negative 
sera (range OD = 0.071–0.111) were added to the neutralization 
assay, as control. These sera were BKPyV negative, as determined 
by HAI. SV40 CPE was hampered or abolished indicating that 
tested sera carried neutralizing Ab against SV40 (Figure  2). 
This result strongly suggests that a SV40 infection occurred in 
pregnant women, tested SV40-positive, whereas the neutralizing 
Ab present in those immune sera were elicited by SV40 and not 
by the homolog BKPyV (30).
DiscUssiOn
Principal Findings of the study
This is the first study providing SV40 LT seroprevalence data for 
pregnant and non-pregnant women, by indirect ELISAs with 
specific LT mimotopes. SV40 infection has been studied in 
healthy individuals of different age, such as children, adults and 
elderly (20, 32–37) and in patients with different cancers found 
to be linked to SV40 (38–43).
This study reports an overall prevalence of 17% in pregnant 
women tested seropositive for SV40 LT Ab (Table  1). These 
findings substantiate previous observations of SV40 LT Ab in 
different age cohorts of normal individuals (24, 25). The over-
all prevalence of SV40 LT IgG Ab (17%) detected in pregnant 
women using indirect ELISAs with mimotopes was similar to that 
reported by previous studies carried out by neutralization assays 
(10.3%) (16) and indirect ELISA with SV40 viral capsid protein 
(VP) mimotopes (13%) (29). The difference among these studies 
is significant because in the present survey, carried out in part 
with new sera from pregnant women and non-pregnant women 
(this study), SV40 LT was the target of the investigation. Indeed, 
SV40 LT, the viral oncoprotein, is responsible of the tumorigenic 
activity in vivo of this small DNA tumor virus. The novelty of this 
investigation can be appreciated if the potential viral oncogenic 
activity of SV40 LT is considered (44), together with the viral DNA 
replication activity driven by the LT (45). SV40 seems to multiply 
in pregnant women with the consequence that SV40 may exert 
its tumorigenic potential in some subjects. The previous reports, 
with immunological data of SV40 viral capsid proteins, indicated 
that SV40 infects humans and that the structural capsid proteins 
elicited specific IgG Ab. The detection of LT Ab in pregnant 
women indicates a potential risk of tumorigenesis for some of 
them and their embryo/fetus/newborn. At the same time, this 
study on the IgG SV40 LT confirms and extends the immunologi-
cal data on SV40 reported in previous investigations.
Taken together, these results provide a comprehensive analysis 
of SV40 seroprevalence during pregnancy. The pregnant women 
analyzed herein were too young to be contaminated by SV40 with 
the early anti-polio vaccines. Indeed, contaminated poliovaccines 
were supposedly SV40 free after 1963, it is unlikely that vaccine 
exposure explains the SV40 antibody positivity of our cohorts 
(29). These data together with previous results indicate that other 
FigUre 2 | inhibition of simian virus 40 (sV40) cytopathic effect (cPe) in cV-1 infected cells by human immune sera. Inhibition of SV40 CPE in infected 
cells by human serum samples from pregnant women and non-pregnant women. Upper panel. (a) Negative control represented by uninfected CV-1 cells.  
(B) Positive control represented by the CPE induced by SV40 in CV-1 infected cells. (c,D) These sera did not inhibit SV40 CPE. (e–g) SV40-positive sera inhibited 
SV40 CPE with different degrees. (h) This serum sample completely inhibited SV40 CPE. Sample H had an optical density (OD) of 0.876 for the LT mimotopes. 
Bottom panel: there was a correlation between the OD values and CPE inhibition activity of tested immune sera. Indeed, serum samples C and D that were under 
the cutoff value did not inhibited SV40 CPE, while sera E, F, and G with an OD in the range of 0.193–0.643 inhibited partially with a different degree SV40 CPE. The 
serum in H panel, with the higher OD value, inhibited completely SV40 CPE.
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sources of SV40 exposure must exist in the human population. Very 
likely, the SV40 reservoir is the human host, whereas the infection 
may reflect the human-to-human contagion. Interestingly, poly-
omaviruses BKPyV, JCPyV, and SV40 have been detected in stool 
and tonsil samples of children and adults indicating that these 
human anatomical sites/specimens could carry these viral agents. 
In turn, infections could occur in the family settings and could 
spread from mother to child, as well. We observed a low SV40 
antibody prevalence in sera of pregnant women, even if there was 
no statistically significant difference from the prevalence found in 
non-pregnant women. This low SV40 prevalence could be due to 
the pregnancy status. Indeed, the pregnancy is a well known con-
dition, which leads to the immune tolerance effect. In addition, in 
pregnant women the increased volume of serum may be respon-
sible of the IgG dilution, which in turn diminished the antibody 
titer. It is also possible that SV40 poorly multiplies in human 
cells, which are only semipermissive to this virus, thus affecting 
SV40 Ab response over time. The transient immune depression/
immune tolerance/IgG dilution associated with pregnancy could 
allow reactivation of latent viruses, including polyomaviruses. In 
this instance, it would be possible that the SV40 transplacental 
transmission from mother to fetus may occur, as demonstrated 
for BKPyV (46), a closely SV40 related human polyomavirus.
BKPyV seroprevalence
The prevalence of BKPyV Ab, although tested herein in a lim-
ited sample size, was approximately 80%, both in pregnant and 
non-pregnant women. These data indicate that the pregnancy 
status does not alter the immune response against the human 
polyomavirus BKPyV.
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Transplacental transmission of polyomaviruses can occur in 
animals, including the murine polyomavirus in mice (47, 48), 
rats (49), and SV40 in hamsters (50, 51). It has been reported 
that BKPyV, which is closely related to SV40, can cross the 
human placenta during pregnancy. Indeed, BKPyV has been 
detected in fetal organs, such as kidney and brain, which are 
tissues were BKPyV remains in the latent state after the primary 
infection (46).
sV40 spread in Pregnant Women
Simian virus 40 infection detected in pregnant women should 
be taken into consideration because of its oncogenic potential. 
Indeed, the immune tolerance could account in some pregnant 
women for the absence/a lower specific immune reactivity 
against this small DNA tumor virus. SV40 after its multiplica-
tion/reactivation in pregnant woman may cross the placenta 
barrier thus infecting the embryo/fetus. If this event occurs, 
SV40 because of its oncogenic potential could be responsible of 
ependymoma and choroid plexus papilloma onset, which are 
pediatric brain tumors arising in children 6  months–2  years 
old (52, 53). It should be recalled that, in previous investiga-
tions these human cancers, together with glioblastoma mul-
tiforme (29, 54, 55) tested SV40-positive at high prevalence 
(6, 38, 56). In conclusion, SV40 LT Ab revealed in sera of 
pregnant women suggest further that SV40, or a closely related 
unknown polyomavirus, infects normal subjects many decades 
after the administration of vaccines contaminated by SV40. 
This result, together with previous data, indicates that SV40 
is now spreading in humans by a person-to-person contagion. 
The health risk due to SV40 infection in normal individuals 
remains to be elucidated. The clinical profile of SV40 infection 
during pregnancy, while requiring additional investigations, is 
of interest because SV40 could be a potential risk for the onset 
of specific cancers found to be associated to the this oncogenic 
virus.
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